No Data
No Data
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Market Cap Dropped CN¥539m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Lushang Freda PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions 53%
Freda (600223): Cosmetics are growing at an accelerated pace, and healthy growth can be expected
Focusing on Big Health and Light Equipment, the compound growth rate of Big Health's performance in 19-23 was 27%. The company's predecessor, Lushang Development, began entering the health sector by acquiring 100% of Shandong Freda Pharmaceutical Group's shares in 18 years, and started the real estate industry in November '22
Concerns Surrounding Lushang Freda PharmaceuticalLtd's (SHSE:600223) Performance
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) healthy profit numbers didn't contain any surprises for investors. We think this is due to investors looking beyond the statutory profits and bei
Freda (600223): Successfully completed the transformation, and the cosmetics business continues to accelerate
The incident describes the company's release of the 2023 annual report. The company achieved operating income of 4.579 billion yuan, a year-on-year decrease of 65%, achieved net profit of 303 million yuan, a year-on-year increase of 567%, and achieved net profit of 139 million yuan after deduction of non-return to mother
Freda (600223) Annual Report Review Report: Performance exceeds the forecast limit, the two-US strategy is expected to drive high-quality growth
Financial indicators fluctuated greatly due to the divestment of real estate, and net profit attributable to the mother exceeded the forecast limit. The company achieved revenue of 4.579 billion yuan (yoy -64.65%) in 2023, mainly due to the divestment of the real estate business, with a net profit of 3.03 billion yuan to the mother
Freda (600223): Cosmetics revenue in '23 YOY +22.2% real estate divestment to achieve company transformation and is optimistic about the company's steady future development
Incident: The company released its 2023 annual report, with annual revenue of 4.579 billion yuan, yoy -64.65%, mainly due to the divestment of the real estate business; net profit to mother was 305 million yuan, yoy +567.44%, and the performance side was higher than before
No Data